Coherus Oncology Q2 2026: LOQTORZI Revenue Climbs 15% QoQ to $13.6M, Pipeline Readouts on Track for 2H 2026
CHRS sits 74% above its 52-week low of $0.81.
Summary
Coherus Oncology reported Q2 2026 LOQTORZI revenue of $13.6 million, up 15% from Q1, and a narrower net loss. Cash of $105.3 million supports operations into 2027, with key pipeline data readouts expected in 2H 2026.
Key Events · Earnings and Guidance · CHRS
-
LOQTORZI Revenue Growth
Q2 2026 net revenue reached $13.6 million, a 15% increase from $11.8 million in Q1 2026 and 37% year-over-year, driven by strong demand and new patient starts.
-
Narrowing Losses
Net loss from continuing operations was $33.3 million ($0.22/share) compared to $44.9 million ($0.39/share) in Q2 2025, reflecting reduced R&D and SG&A expenses.
-
Cash Position
Cash, cash equivalents and marketable securities totaled $105.3 million as of June 30, 2026, down from $172.1 million at year-end 2025, providing runway into 2027.
-
Pipeline Catalysts Ahead
Multiple data readouts are expected in 2H 2026: tagmokitug Phase 1b/2a studies in HNSCC, CRC, and ESCC; casdozokitug Phase 2 in HCC with enrollment complete; and a projected October public disclosure of mature data sets.
Analysis · CHRS · Life Sciences
Coherus posted Q2 2026 results with LOQTORZI net revenue rising 15% sequentially to $13.6 million, fueled by robust demand and new patient starts. The net loss from continuing operations narrowed to $33.3 million from $44.9 million a year ago, underscoring cost discipline. Cash stood at $105.3 million as of June 30, 2026, down from $172.1 million at year-end 2025, highlighting ongoing cash burn. On the pipeline front, enrollment is complete in the casdozokitug Phase 2 HCC trial, and multiple tagmokitug studies are advancing with initial data expected in the second half of 2026, including a projected October data disclosure. These catalysts could unlock significant value if positive, but the company remains unprofitable and will need additional capital to fund operations through these readouts.
At the time of this filing, CHRS was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $223.7M. The 52-week trading range was $0.81 to $2.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.